0.9950USD-7.01%Mkt Cap: 34.37M USDP/E: —Last update: 2026-05-26
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed it…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap34.37M USD
Enterprise Value29.88M USD
Revenue (TTM)—
Gross Profit-1.88M USD
Net Income (TTM)-15.95M USD
Revenue/Share—
Last Price0.9950 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG2.22
EV/EBITDA-1.75
EV/Revenue—
P/S—
P/B0.49
EPS (TTM)-2.08
EPS (Forward)—
52W Range
0.95001% of range9.000
52W High9.000 USD
52W Low0.9500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-94.18%
ROA-87.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.84M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-41.34%
Net Debt-7.54M USD
Net Debt/EBITDA0.44
Balance Sheet
Debt/Equity—
Current Ratio11.53
Quick Ratio7.92
Book Value/Sh2.233 USD
Cash/Share0.2220 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateNov 16, 2023
Pay DateDec 6, 2023
Splits
Last Split1:20
Split DateApr 17, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.34.03M
Float28.55M
Insiders11.96%
Institutions17.32%
Short Interest
Short Ratio0.4d
Short % Float0.30%
Short % Out.0.26%
Shares Short95.31K
Short (prev mo.)92.17K
Technical
SMA 501.162 (-14.4%)
SMA 2001.952 (-49.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)356.84K
Avg Vol (10d)444.75K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—